Novo Nordisk ramps up obesity fight, advances amycretin to Phase III
Novo Nordisk is making moves to retain its market share in the weight loss space.
13 June 2025
13 June 2025
Novo Nordisk is making moves to retain its market share in the weight loss space.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.